SequelSEC

GALECTIN THERAPEUTICS INC GALT

Pharmaceutical Preparations · CIK 0001133416 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$20.08M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

GALECTIN THERAPEUTICS INC (GALT) reported net income of -$30.84M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from GALECTIN THERAPEUTICS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

GALECTIN THERAPEUTICS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$20.08M-$42.43M-$38.07M-$38.35M-$30.18M-$23.44M-$13.44M-$13.60M-$16.25M-$21.48M
Net income-$30.84M-$47.05M-$41.07M-$38.78M-$30.53M-$23.46M-$13.29M-$13.90M-$16.24M-$21.44M
Research & development$14.29M$36.57M$32.13M$31.74M$23.82M$17.98M$7.47M$6.47M$11.72M$15.32M
Weighted-average diluted sharesshares 63.90Mshares 62.31Mshares 60.16Mshares 59.39Mshares 58.53Mshares 57.03MUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.48$-0.76$-0.74$-0.65$-0.52$-0.41UnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$5.80M$5.86M$5.94M$6.62M$6.36M$5.47M$5.97M$7.13M$4.53M$6.16M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

GALECTIN THERAPEUTICS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$17.72M$15.12M$25.66M$18.59M$39.65M$27.14M$47.48M$8.25M$3.05M$15.36M
Total assets$19.53M$17.50M$28.20M$21.28M$41.83M$29.60M$48.47M$9.01M$4.16M$15.80M
Current assets$19.44M$17.25M$27.71M$20.55M$41.82M$29.46M$48.21M$8.83M$3.82M$15.79M
Total liabilities$145.73M$120.56M$88.44M$53.48M$39.21M$5.41M$2.87M$2.11M$2.97M$3.78M
Current liabilities$8.03M$35.41M$15.68M$13.01M$9.03M$5.40M$2.82M$2.11M$2.97M$3.78M
Total equity incl. NCI-$127.92M-$104.79M-$61.96M-$33.92M$893.00K$22.47M$43.87M$5.18M-$530.00K$10.29M
Temporary (mezzanine) equity$1.72M$1.72M$1.72M$1.72M$1.72M$1.72M$1.72M$1.72MUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.24M$5.66M$6.43M$3.89M$1.80M$1.29M$1.66M$297.00K$608.00K$910.00K

Cash flow

GALECTIN THERAPEUTICS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$23.88M-$41.77M-$32.96M-$31.06M-$24.31M-$20.60M-$10.85M-$10.18M-$15.89MUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$0$0$0$0$0$0Unavailable$0$0Unavailable
Financing cash flow$26.48M$31.23M$40.03M$10.00M$36.81M$263.00K$50.08M$15.38M$3.58MUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$5.20M-$12.31M-$10.48M
Stock-based compensation$1.66M$2.45M$2.26M$2.87M$2.08M$1.80M$1.68M$4.44M$1.10M$2.48M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailable$0$0$0$0$0$0$0$1.00K$7.00K

Derived

GALECTIN THERAPEUTICS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio2.42x0.49x1.77x1.58x4.63x5.46x17.10x4.19x1.29x4.18x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GALT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2017-12-31

Difference 1723000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2016-12-31

Difference 1723000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.